Marinus Pharmaceuticals Inc

NASDAQ:MRNS

13.50

+0.30 (+2.27%)

Market Cap (Intraday)	491.79M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.2 Million
Adjusted EPS	-$0.52

See more estimates

10-Day MA	$12.93
50-Day MA	$13.50
200-Day MA	$10.87

See more pivots

MARINUS PHARMACEUTICALS INC Stock, NASDAQ:MRNS

170 N RADNOR CHESTER RD, SUITE 250, RADNOR, PA 19087

United States of America

Phone: 484-801-4670

Number of Employees: 28

www.marinuspharma.com

Description

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.